Advice
Following a full submission
montelukast chewable tablet and granules (Singulair Paediatric) is accepted for restricted use within NHS Scotland as an alternative treatment option to low-dose inhaled corticosteroids for patients, [children 2 to 14 years of age] with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.
It should be restricted to initiation by specialists in paediatric asthma care.
Download detailed advice90KB (PDF)
Medicine details
- Medicine name:
- montelukast (Singulair paediatric)
- SMC ID:
- 383/07
- Indication:
- Asthma in Children aged 2 -14 years
- Pharmaceutical company
- MSD
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 July 2007